CABA

Cabaletta Bio, Inc. [CABA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CABA Stock Summary

Top 10 Correlated ETFs

CABA


Top 10 Correlated Stocks

CABA


In the News

02:53 29 Mar 2024 CABA

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.

02:44 29 Mar 2024 CABA

Buy Cabaletta Bio's Promising SLE Treatment

Cabaletta Bio is a biotech company with promising CARTA and CAART therapies for autoimmune diseases. Their main research project, CABA-201, targets patients suffering from SLE, opening up a huge market with significant revenue potential. The company is well-capitalized and has a cash runway that extends beyond 2025, making it a good long-term investment.

03:55 29 Mar 2024 CABA

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Shares of Cabaletta Bio Inc. CABA, Gracell Biotechnologies Inc. GRCL and other smaller biotech companies involved in developing CAR-T cell therapies plunged Tuesday after the Food and Drug Administration said it was investigating cancer risks potentially associated with all currently approved products in the class.

08:00 29 Mar 2024 CABA

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in three upcoming investor conferences in November:

11:17 29 Mar 2024 CABA

Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?

Here is how Cabaletta Bio, Inc. (CABA) and KalVista Pharmaceuticals, Inc. (KALV) have performed compared to their sector so far this year.

10:31 29 Mar 2024 CABA

What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing'

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

08:00 29 Mar 2024 CABA

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September:

04:56 29 Mar 2024 CABA

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on autoimmune conditions with a validated cell therapy approach, rather than oncology, has been a key factor in its success. Cabaletta's cell therapy CABA-201 targeting Lupus Nephritis has had its MoA validated by an academic study, leading to increased investor interest and a rise in share price.

10:32 29 Mar 2024 CABA

Cabaletta Bio, Inc. (CABA) is on the Move, Here's Why the Trend Could be Sustainable

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

08:30 29 Mar 2024 CABA

The 7 Most Promising Momentum Stocks to Own Now

Today's volatile market makes momentum investing a compelling strategy for those comfortable with daily turbulence. Unlike value investing, which is rooted in purchasing undervalued assets, momentum investing hinges on the principle that assets that have performed well recently will continue to do so in the near future.

CABA Financial details

Company Rating
Neutral
Market Cap
743.44M
Income
-60.57M
Revenue
0
Book val./share
3.82
Cash/share
3.9
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-16.65
Forward P/E
-9.14
PEG
5.73
P/S
-
P/B
6.26
P/C
4.38
P/FCF
-20.5
Quick Ratio
15.49
Current Ratio
15.65
Debt / Equity
0.03
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.71
EPS next Y
-1.87
EPS next Q
-0.41
EPS this Y
-31.54%
EPS next Y
9.59%
EPS next 5Y
16.96%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-26.09%
SMA50
-22.73%
SMA100
21.43%
Inst Own
75.57%
Inst Trans
0.7%
ROA
-35%
ROE
-46%
ROC
-0.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
48.24M
Shs Float
38M
-
-
-
-
Target Price
16.33
52W Range
6.94-26.35
52W High
-34.27%
52W Low
+184.83%
RSI
33
Rel Volume
0.63
Avg Volume
899.34K
Volume
567.73K
Perf Week
-5.68%
Perf Month
-28.49%
Perf Quarter
9.48%
Perf Half Y
11.19%
-
-
-
-
Beta
2.457
-
-
Volatility
0.23%, 2.48%
Prev Close
-0.35%
Price
17.09
Change
-0.12%

CABA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.76-1.4-13.68-2.410
Operating cash flow per share
-2.93-1.16-10.25-2.150
Free cash flow per share
-3.06-1.18-10.6-2.270
Cash per share
24.94.6936.724.950
Book value per share
25.294.7335.444.850
Tangible book value per share
25.294.7335.444.850
Share holders equity per share
25.294.7335.444.850
Interest debt per share
0000.180
Market cap
76.41M288.85M12.62M199.19M0
Enterprise value
-59.8M187.42M-109.61M122.72M-188.22M
P/E ratio
-5.06-8.89-0.28-3.840
Price to sales ratio
00000
POCF ratio
-4.76-10.79-0.37-4.290
PFCF ratio
-4.56-10.54-0.36-4.080
P/B Ratio
0.552.640.111.910
PTB ratio
0.552.640.111.910
EV to sales
00000
Enterprise value over EBITDA
3.2-5.542.37-2.272.52
EV to operating cash flow
3.73-73.21-2.653.51
EV to free cash flow
3.57-6.843.11-2.513.47
Earnings yield
-0.2-0.11-3.61-0.260
Free cash flow yield
-0.22-0.09-2.8-0.250
Debt to equity
0000.050.02
Debt to assets
0000.040.02
Net debt to EBITDA
7.2932.641.412.52
Current ratio
44.6621.9214.8611.4715.29
Interest coverage
00045.960
Income quality
0.950.80.740.880.79
Dividend Yield
0.130000
Payout ratio
-0.670000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.040.020.030.050.01
Capex to revenue
00000
Capex to depreciation
-6.66-1.79-1.59-2.08-0.48
Stock based compensation to revenue
00000
Graham number
39.6312.23104.4316.210
ROIC
-0.12-0.3-0.39-0.46-0.3
Return on tangible assets
-0.11-0.28-0.36-0.44-0.27
Graham Net
24.334.4734.24.370
Working capital
137.41M108.36M116.16M99.35M228.5M
Tangible asset value
138.32M109.54M117.96M104.52M236.2M
Net current asset value
137.41M108.36M116.16M96.39M227.04M
Invested capital
0000.050.02
Average receivables
00000
Average payables
761.5K1.08M1.79M2.4M3.51M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
3.23K1.28K1.16K244.030
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.110.280.311.50
Inventory turnover
00000
ROE
-0.11-0.3-0.39-0.5-0.29
Capex per share
-0.13-0.03-0.35-0.110

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.38-0.51-0.42-0.39-0.39
Operating cash flow per share
-0.34-0.41-0.36-0.32-0.3
Free cash flow per share
-0.38-0.42-0.37-0.32-0.3
Cash per share
2.963.622.654.733.9
Book value per share
2.963.552.594.673.82
Tangible book value per share
2.963.552.594.673.82
Share holders equity per share
2.963.552.594.673.82
Interest debt per share
0.010.160.10.110.1
Market cap
18.86M272.37M293.16M481.7M640.92M
Enterprise value
-42.3M195.9M203.99M357.82M529.69M
P/E ratio
-0.43-4.58-4.97-8.31-9.74
Price to sales ratio
00000
POCF ratio
-1.9-22.45-23.25-40.52-50.85
PFCF ratio
-1.71-21.88-22.57-40.32-50.59
P/B Ratio
0.222.613.22.773.98
PTB ratio
0.222.613.22.773.98
EV to sales
00000
Enterprise value over EBITDA
3.71-12.02-12.3-23.06-28.37
EV to operating cash flow
4.27-16.15-16.18-30.1-42.03
EV to free cash flow
3.84-15.74-15.71-29.95-41.81
Earnings yield
-0.59-0.05-0.05-0.03-0.03
Free cash flow yield
-0.58-0.05-0.04-0.02-0.02
Debt to equity
00.050.050.020.03
Debt to assets
00.040.050.020.02
Net debt to EBITDA
5.364.695.377.985.96
Current ratio
15.211.4710.2920.9415.65
Interest coverage
-33.5632.5415.3900
Income quality
0.870.770.80.820.77
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.110.030.0300.01
Capex to revenue
00000
Capex to depreciation
-3.01-0.88-1.04-0.15-0.18
Stock based compensation to revenue
00000
Graham number
5.046.354.926.395.8
ROIC
-0.13-0.13-0.16-0.09-0.11
Return on tangible assets
-0.12-0.13-0.14-0.08-0.09
Graham Net
2.763.22.314.443.61
Working capital
82.37M99.35M86.43M169.09M155.56M
Tangible asset value
85.87M104.52M91.65M174.14M160.92M
Net current asset value
82.37M96.39M83.94M167.08M153.81M
Invested capital
00.050.050.020.03
Average receivables
00000
Average payables
1.89M1.9M3.21M3.15M2.98M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
330.577.4435.68252.93917.75
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.271.160.210.360.1
Inventory turnover
00000
ROE
-0.13-0.14-0.16-0.08-0.1
Capex per share
-0.04-0.01-0.0100

CABA Frequently Asked Questions

What is Cabaletta Bio, Inc. stock symbol ?

Cabaletta Bio, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol CABA

Is Cabaletta Bio, Inc. buy or a sell ?